CB-5339 is a targeted protein degrader designed to selectively degrade specific proteins involved in cancer cell proliferation. It functions by recruiting E3 ubiquitin ligases to tag disease-causing proteins for proteasomal destruction, offering a novel approach in oncology therapeutics. This compound shows promise in treating hematologic malignancies, particularly acute myeloid leukemia (AML), where traditional therapies have limited efficacy. Its mechanism allows for the targeting of previously "undruggable" proteins, providing a strategic advantage in drug development. Preclinical studies indicate potent anti-tumor activity with reduced off-target effects, making CB-5339 a candidate for further clinical evaluation in precision cancer treatment.